Swiss Life Asset Management Ltd Decreases Position in Pfizer Inc. $PFE

Swiss Life Asset Management Ltd reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,702,699 shares of the biopharmaceutical company’s stock after selling 126,498 shares during the quarter. Pfizer accounts for approximately 0.8% of Swiss Life Asset Management Ltd’s holdings, making the stock its 21st largest holding. Swiss Life Asset Management Ltd owned about 0.10% of Pfizer worth $145,305,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer during the third quarter worth $29,000. Howard Hughes Medical Institute acquired a new position in Pfizer in the 2nd quarter worth $30,000. Darwin Wealth Management LLC acquired a new stake in shares of Pfizer during the second quarter valued at about $32,000. Evelyn Partners Asset Management Ltd acquired a new stake in shares of Pfizer during the second quarter valued at about $33,000. Finally, True Wealth Design LLC increased its position in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PFE. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. Citigroup initiated coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Bank of America dropped their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, HSBC raised their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.14.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 topline — Pfizer reported positive topline results from the Phase 3 TALAPRO-3 study showing TALZENNA (talazoparib) plus XTANDI (enzalutamide) significantly improved radiographic progression‑free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer, a meaningful late‑stage win that could expand a high‑value oncology franchise. TALAPRO-3 Topline
• Positive Sentiment: Mid‑stage breast cancer data supports pipeline — Pfizer’s Phase 2 FOURLIGHT‑1 trial of atirmociclib met its primary endpoint in second‑line HR+/HER2‑ metastatic breast cancer, cutting risk of progression and strengthening Pfizer’s bid to follow on from CDK4/6 leaders (Ibrance, etc.). This readout is being positioned as a key oncology catalyst. Atirmociclib Phase 2 Results
• Positive Sentiment: Analyst upgrade and price‑target lift — HSBC raised its price target to $32 and moved to a buy rating, citing upside to Pfizer’s valuation; that upgrade has drawn investor attention and provided near‑term support. HSBC Upgrade
• Neutral Sentiment: Early‑stage liver program advanced — Pfizer updated progress on a Phase 1 PF‑07328948 liver study, which modestly supports the pipeline but is an early, lower‑visibility catalyst. PF‑07328948 Liver Study
• Neutral Sentiment: Public commentary and investor interest — Media/columnist coverage (including Jim Cramer) and various valuation pieces have increased attention on PFE, driving trading volume but not a clear directional catalyst. Cramer & Media Coverage
• Negative Sentiment: Program trimming: early‑stage melanoma study ended — Pfizer discontinued an early‑stage melanoma study (PF‑08046031), which trims one oncology bet and tempers the otherwise bullish pipeline narrative. Melanoma Study Stop
• Negative Sentiment: Industry pricing scrutiny — A Reuters/analysis piece on TrumpRx highlights continued political scrutiny of U.S. drug prices; broader policy and pricing headlines can pressure large pharma multiples and investor sentiment for companies like Pfizer. TrumpRx Pricing Analysis

Pfizer Stock Performance

PFE stock opened at $27.33 on Thursday. The stock’s 50 day simple moving average is $26.61 and its 200 day simple moving average is $25.57. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94. The firm has a market cap of $155.38 billion, a P/E ratio of 20.09 and a beta of 0.47. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.63 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.